Cargando…

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls

Detalles Bibliográficos
Autores principales:	Haar, Nienke Ter, Holzinger, Dirk, de Jager, Wilco, Scholman, Rianne, de Roock, Sytze, Vastert, Bas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4184146/ http://dx.doi.org/10.1186/1546-0096-12-S1-O24

Ejemplares similares

S100A12 as diagnostic tool in the differential diagnosis of sJIA associated MAS vs. hereditary or acquired HLH
por: Holzinger, D, et al.
Publicado: (2015)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
por: Livermore, P, et al.
Publicado: (2008)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)
por: Kumar, Sharath, et al.
Publicado: (2012)

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
por: Bullement, Ash, et al.
Publicado: (2021)

Interferon-gamma (IFNy) in macrophage activation syndrome (MAS) associated with systemic juvenile idiopathic arthritis (sJIA). High levels in patients and a role in a murine mas model
por: Bracaglia, Claudia, et al.
Publicado: (2014)

Mitochondrial and oxidative stress genes are differentially expressed in neutrophils of sJIA patients treated with tocilizumab: a pilot microarray study
por: Omoyinmi, Ebun, et al.
Publicado: (2016)

Severe sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
por: Xu, Meng, et al.
Publicado: (2020)

Prolonged Fever in a Pediatric Patient: A Case of Systemic Juvenile Idiopathic Arthritis (sJIA) Complicated by Macrophage Activation Syndrome (MAS)
por: Cortes, Marianne, et al.
Publicado: (2023)

Recombinant IL1-RA in the early phase of systemic onset JIA: before the onset of arthritis
por: Vastert, SJ, et al.
Publicado: (2011)

Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients
por: de Jager, W, et al.
Publicado: (2011)

P02-029 - CAPS or SJIA
por: Alekseeva, E, et al.
Publicado: (2013)

Monocytes and neutrophils in the inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis
por: ter Haar, N, et al.
Publicado: (2015)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

Mutations of familial hemophagocytic lymphohistiocytosis (FHL) related genes and abnormalities of cytotoxicity function tests in patients with macrophage activation syndrome (MAS) occurring in systemic juvenile idiopathic arthritis (sJIA)
por: Bracaglia, Claudia, et al.
Publicado: (2014)

Serious infections in JIA patients upon MTX, TFN inhibitors and combinations
por: Horneff, Gerd, et al.
Publicado: (2014)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study
por: Mirjafari, H, et al.
Publicado: (2013)

IL-1 receptor antagonist restores IL-18 NK cell axis in systemic JIA
por: Vastert, Sebastiaan J, et al.
Publicado: (2012)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
por: de Roock, Sytze, et al.
Publicado: (2011)

PReS-FINAL-2178: Clinical and microarray follow-up of SJIA patients treated with anakinra over the past 10 years in a single institution
por: Punaro, M, et al.
Publicado: (2013)

4.4 Different phenotype of anaemia in systemic juvenile idiopathic arthritis (s-JIA) compared to anaemia in other subtypes of JIA
por: Hinze, CH, et al.
Publicado: (2008)

To evaluate the impact of a nurse-led JIA education program on parental satisfaction regarding knowledge of JIA and its management
por: Jones, J, et al.
Publicado: (2011)

Can inflammatory markers predict response to methotrexate in JIA? Results from the CHARM study
por: Moncrieffe, H, et al.
Publicado: (2011)

Histone antibodies as a biomarker of uveitis in JIA
por: Nordal, Ellen B, et al.
Publicado: (2014)

Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still’s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity
por: Kudela, Holger, et al.
Publicado: (2019)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

The human microbiome and juvenile idiopathic arthritis
por: Verwoerd, Anouk, et al.
Publicado: (2016)

Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
por: Ravelli, A, et al.
Publicado: (2014)

Accuracy of preliminary remission criteria some JIA category
por: Fantini, F, et al.
Publicado: (2008)

The effects of early aggressive therapy in JIA: results of the TREAT study
por: Wallace, Carol A, et al.
Publicado: (2012)

Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
por: Ravelli, A, et al.
Publicado: (2014)

Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) Show Differences in Autoantibody Signatures Based on Disease Activity
por: Krainer, Julie, et al.
Publicado: (2023)

Epidemiology of JIA
por: Lahdenne, Pekka
Publicado: (2014)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
por: De Benedetti, F, et al.
Publicado: (2011)

Safety and efficacy of varicella vaccination in children with JIA treated with biologic therapy
por: Toplak, Natasa, et al.
Publicado: (2014)

PReS-FINAL-2002: Adverse events during anti-TNF therapy in patients with JIA
por: Tarkiainen, M, et al.
Publicado: (2013)

JIA pathogenesis - genetics
por: Thomson, Wendy
Publicado: (2014)

Response to Jia and Wang
por: Liu, Xu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_696hcar9lpnekq9e190hlctmj7